Promise for the dark disease of glaucoma | Valley Life | avpress.com – Antelope Valley Press


Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.
Please log in, or sign up for a new account to continue reading.
Thank you for reading! We hope that you continue to enjoy our free content.
Please log in, or sign up for a new account and purchase a subscription to continue reading.
Please purchase a subscription to continue reading.
Your current subscription does not provide access to this content.
Sorry, no promotional deals were found matching that code.
Promotional Rates were found for your code.
Sorry, an error occurred.

do not remove
Windy with rain developing this afternoon. Morning high of 58F with temps falling to near 45. Winds SW at 35 to 50 mph. Chance of rain 90%. Rainfall near a half an inch. Winds could occasionally gust over 60 mph..
Showers early, then partly cloudy overnight. Low 41F. Winds SW at 15 to 25 mph. Chance of rain 40%. Higher wind gusts possible.
Updated: November 8, 2022 @ 12:08 pm
Windy with rain developing this afternoon. Morning high of 58F with temps falling to near 45. Winds SW at 35 to 50 mph. Chance of rain 90%. Rainfall near a half an inch. Winds could occasionally gust over 60 mph..
Showers early, then partly cloudy overnight. Low 41F. Winds SW at 15 to 25 mph. Chance of rain 40%. Higher wind gusts possible.
Updated: November 8, 2022 @ 12:08 pm

Beware the “silent thief of sight.” Glaucoma sneaks up on people causing irreparable vision loss before diagnosis. Over 3 million North Americans have glaucoma — about half don’t know it. For society, the economic and social consequences of stolen sight is large. For sufferers, when glaucoma progresses to blindness, it is life changing. But is a cure in sight?
The field of stem cell research is moving at lighting speed.
In the search for a cure to glaucoma, adult stem cells, as opposed to the more controversial embryonic stem cells, are the focus. There are two types of adult stems cells. One type comes from tissues such as the brain, skin or bone marrow. This type only makes more of the same. A stem cell from the liver only makes more liver cells.
Another type is called “induced pluripotent stem cells,” which are programmable. They were discovered, in 2006, by Dr. Shinya Yamanaka. He collected a Nobel Prize, in 2012, having been the first to achieve success in showing that these stems cells can self-renew indefinitely and change into other cell types.
Less than a decade after discovery, the first surgical implant of these cells occurred in the eye of a Japanese patient using her own reprogrammed skin cells, grown in a lab into a sheet of retina cells to fight, in this case, macular degeneration.
Dr. Yvonne Ou is a Harvard Medical School-trained ophthalmologist and glaucoma specialist at the University of California, San Francisco, Medical Center. She notes that the use of stem cells in the treatment of glaucoma includes a variety of approaches.
Open-angle glaucoma is the most common form of this disease, where eye pressure builds gradually causing vision issues over time, not suddenly as in the other form of glaucoma that causes an urgent medical emergency.
“In primary open-angle glaucoma,” Dr. Ou explains, “the drainage system does not properly drain the fluid inside the eye, and eye pressure can increase. One idea is to take pluripotent stem cells and use them to make the cells that drain fluid out of the eye in an effort to restore the eye’s drainage system.”
Currently, eyedrops and laser treatments help glaucoma patients lower eye pressure, but there is no potential for restoration of damage, as promised by stem cells.
Stem cells may also offer hope in repairing the cells in the eyes that transmit information. These neurons create the pathway between the retina and the brain, and when they die, vision is lost. Scientists are studying the potential for adult stem cells to be transformed into these neurons, transplanted in the eye, and then encouraged to reach out and connect with the retina and the brain.
Accomplishing this goal would certainly be worthy of another Nobel Prize. The race is on, and not just in glaucoma research. Other diseases like Parkinson’s are the subject of similar studies.
Until there is a breakthrough though, prevention is still the best strategy.
But here is the alarming truth and the reason glaucoma is still the silent thief.
It is estimated that about 3 million North Americans have glaucoma, and nearly half of them don’t know it. One survey by Prevent Blindness America found that 30% of those surveyed had never heard of glaucoma.
Vision loss from glaucoma is a tragedy, as a series of simple eye exams can detect disease early and existing treatments are effective in reducing further damage.
From early in life, and all through it, a healthy diet rich in green leafy vegetables is an excellent antidote to glaucoma too.
Sign up at www.docgiff.com to receive our weekly e-newsletter. For comments, [email protected]. Follow us on Instagram @docgiff and @diana_gifford_jones
Your comment has been submitted.

Reported
There was a problem reporting this.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.
Sorry, there are no recent results for popular videos.
Success! An email has been sent to with a link to confirm list signup.
Error! There was an error processing your request.
Have the latest local news delivered every afternoon so you don’t miss out on updates.
Find out what’s happening with the latest events in our community.

source


Leave a Reply

Your email address will not be published.